Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy

INTRODUCTION: The benefit of annual administration of zoledronic acid in the management of thalassemia-associated osteoporosis is unknown. AIM: The aims of this study were to evaluate the efficacy of treatment with two different dosing regimens of IV zoledronic acid (annually versus every 3 months)...

Descripción completa

Detalles Bibliográficos
Autores principales: Darvishi-Khezri, Hadi, Kosaryan, Mehrnoush, Akbarzadeh, Rosseta, Aliasgharian, Aily, Fazli, Mehran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Medical Sciences of Bosnia and Herzegovina 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021158/
https://www.ncbi.nlm.nih.gov/pubmed/30061760
http://dx.doi.org/10.5455/medarh.2018.72.170-173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021158/
https://www.ncbi.nlm.nih.gov/pubmed/30061760
http://dx.doi.org/10.5455/medarh.2018.72.170-173

Ejemplares similares